Onconetix's Proteomedix Board Welcomes Back Proclarix Co-Developer
Event summary
- Ralph Schiess, PhD, co-founder of Proteomedix and co-developer of Proclarix®, rejoins the board of Onconetix's Swiss subsidiary.
- Thomas Meier, PhD, re-elected as Chairman of Proteomedix AG at the Annual General Meeting held on June 22, 2026.
- Schiess brings over a decade of academic and diagnostic industry experience, including leading Proclarix® from prototype to commercial product.
The big picture
Onconetix's move to bring back Ralph Schiess underscores the strategic importance of Proclarix® in its oncology portfolio. The appointment signals a focus on deepening diagnostic capabilities, particularly as Onconetix navigates regulatory pathways for U.S. market entry. Schiess's dual role at ZH3D and Proteomedix may also bridge academic research with commercialization efforts, aligning with broader industry trends toward translational medicine.
What we're watching
- Strategic Alignment
- How Schiess's return will influence Proteomedix's integration within Onconetix and Proclarix®'s commercial expansion.
- Regulatory Pathways
- The pace at which Onconetix advances Proclarix® in the U.S. through its Labcorp partnership, following EU approval.
- Commercial Execution
- Whether Proteomedix can leverage Schiess's expertise to expand Proclarix®'s market reach beyond prostate cancer diagnostics.
Related topics